2021 / 02

DOI: 10.47183/mes.2021.019

METHOD

Method for quantitative assessment of protective immunity against SARS-CoV-2, its duration and antibody dynamics

Karmishin AM1, Nosov NYu1, Postupailo VB1, Zhigarlovskiy BA1, Kruglov AA1, Petukhov AN2
About authors

1 Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical Biological Agency, Moscow, Russia

2 Military Academy of Radiation, Chemical and Biological Defense, Kostroma, Russa

Correspondence should be addressed: Alexandr M. Karmishin
Shchukinskaya, 5/6, Moscow, 123182; ur.zmpsc@nihsimraka

About paper

Author contribution: All authors equally contributed to the methodology of the study, data acquisition, analysis and interpretation. All author participated in drafting the manuscript and editing its final version.

Received: 2021-05-25 Accepted: 2021-06-07 Published online: 2021-06-28
|
  1. Ye Q, Wang B, Mao J, Fu J, Shang S, Shu Q, et al. Epidemiological analysis of COVID-19 and practical experience from China. J Med Virol. 2020 Jul; 92 (7): 755–69. DOI: 10.1002/jmv.25813. Epub 2020 Apr 10. PMID: 32237160; PMCID: PMC7228220.
  2. Li K, Huang B, Wu M, et al. Dynamic changes in anti-SARSCoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19. Nat Commun 11, 6044 (2020). Available from: https://doi.org/10.1038/s41467-020-19943-y.
  3. Sun B, Feng Y, Mo X, Zheng P, Wang Q, Li P, et al. Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients. Emerg Microbes Infect. 2020 Dec; 9 (1): 940–8. DOI: 10.1080/22221751.2020.1762515. PMID: 32357808; PMCID: PMC7273175.
  4. Karmishin AM, Borisevich IV, Kruglov AA, Nosov NYu, Postupajlo VB, Zhigarlovskij BA, i dr. Teoreticheskie aspekty modelirovanija jepidemii COVID-19. VV RHB zashhity. 2020; 4 (90): 73–88. Russian.
  5. Postupajlo VB, Karmishin AM, Nosov NYu, Zhigarlovskij BA; zajavitel' i pravoobladatel'. Sposob opredelenija kolichestvennyh harakteristik processa inficirovanija naselenija SARS-CoV-2 v razlichnyh stranah. Svidetel'stvo o gosudarstvennoj registracii bazy dannyh # 2021620762 Rossijskaja Federacija; zjavl. 05.04.2021; gosregistracija 16.04.2021. Russian.
  6. Karmishin AM., Gumenjuk VI, Makarov ML. Teoreticheskie aspekty obosnovanija kolichestvennyh pokazatelej opasnosti avarij potencial'no opasnyh promyshlennyh ob"ektov. Problemy bezopasnosti i chrezvychajnyh situacij 2019; 2: 51–66. Russian.
  7. Karmishin AM, Borisevich IV, Skvorcova VI, Gorjaev AA, Judin SM. Verojatnost' vozniknovenija infekcionnogo zabolevanija cheloveka pri jepidemii. Medicina jekstremal'nyh situacij. 2021; 1: 5–11. DOI: 10.47183/mes.2021.007. Russian.
  8. Lei Q, Li Y, Hou HY, et al. Antibody dynamics to SARS–CoV–2 in asymptomaticCOVID–19infections. Allergy. 2021; 76: 551–61. Aailable from: https://doi.org/10.1111/all.14622.
  9. Dronina AM, Guzovskaja TS, Severinchik IV, Bandackaja MI, Chistenko GN. Osnovy immunoprofilaktiki: uchebno-metodicheskoe posobie. Minsk: BMGU, 2019; 138 s. Russian.
  10. Instrukcija po medicinskomu primeneniju lekarstvennogo preparata Gam-KOVID-Vak. Kombinirovannaja vektornaja vakcina dlja profilaktiki koronavirusnoj infekcii, vyzyvaemoj virusom SARS-CoV-2. Aailable from: https://grls.rosminzdrav. ru/Grls_View_v2.aspx?routingGuid=44bf0ff3-f94e-4c42-954ea4c53811576c&t. (Ssylka aktivna na 22 aprelja 2021). Russian.
  11. Instrukcija po medicinskomu primeneniju lekarstvennogo preparata «JepiVakKorona». Vakcina na osnove peptidnyh antigenov dlja profilaktiki COVID-19. Dostupno po ssylke: https:// grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=fa7efa734f93-4e05-b467-03998160616d&t. (Ssylka aktivna na 22 aprelja 2021). Russian.
  12. REG 174 information for UK healthcare professionals. Aailable from: https://assets.publishing.service.gov.uk/government/ uploads/system/uploads/attachment_data/file/978194/uk-HCPcovid-19-vaccine-astrazeneca-reg174_proposed_14_Apr_2021. pdf. (Ссылка активна на 22 апреля 2021).
  13. Fact sheet for recipients and caregivers emergency use authorization (EUA) of the Moderna covid-19 vaccine to prevent coronavirus disease 2019 (COVID-19) in individuals 18 years of age and older. Aailable from: https://www.modernatx.com/ covid19vaccine-eua/eua-fact-sheet-recipients.pdf. (Ссылка активна на 22 апреля 2021).
  14. Fact sheet for recipients and caregivers emergency use authorization (EUA) of the Pfizer-BioNTech COVID-19 Vaccine to prevent Coronavirus Disease 2019 (COVID-19) in individuals 16 years of age and older. Aailable from: https://www.fda.gov/ media/144414/download. (Ссылка активна на 22 апреля 2021). 15. Karmishin AM, Kireev VA, Berezin GI, Afanasev RV.
  15. Matematicheskie metody farmakologii, toksikologii i radiobiologii. M.: OOO «APR», 2011; 330 s. Russian.
  16. Karmishin AM. K voprosu o bezopasnoj doze toksichnyh himicheskih veshhestv. V sbornike: V. R. Rembovskij, redaktor. Materialy Vserossijskoj nauchno-prakticheskoj konferencii, posvjashhennoj 55-letiju FGUP «NII GPJeCh» FMBA Rossii, 17 fevralja 2017 g., g. Sankt-Peterburg. SPb.: Izd. Politehn. un-ta, 2017; s. 64–66. Russian.
  17. Karmishin AM, Nosov NYu, Zhigarlovskij BA, Postupajlo VB. Bezopasnaja doza toksichnyh himicheskih veshhestv. V sbornike: Materialy I Nacional'nogo kongressa s mezhdunarodnym uchastiem po jekologii cheloveka, gigiene i medicine okruzhajushhej sredy «SYSINSKIE ChTENIJa — 2020» Moskva, 19-20 nojabrja 2020 g. M.: FGBU «CSP» FMBA Rossii, 2020; s. 168–72. Russian.
  18. Kombarova SYu, Aleshkin AV, Novikova LI, Bochkareva SS, Karpov OYe, Pulin AA, i dr. Dinamika antitel k razlichnym antigenam koronavirusa SARS-CoV-2 u bol'nyh s podtverzhdennoj infekciej Covid-19. 2020. COVID19-PREPRINTS.MICROBE.RU. Dostupno po ssylke: https://doi.org/10.21055/preprints-3111756. Russian.
  19. Popova AYu, Ezhlova EB, Melnikova AA, Andreeva EE, Kombarova SYu, Ljalina LV, i dr. Kollektivnyj immunitet k SARS-CoV-2 zhitelej Moskvy v jepidemicheskij period COVID-19. Infekcionnye bolezni. 2020; 18 (4): 8–16. DOI: 10.20953/1729-9225-2020-4-8-16. Russian.